Cardiome Pharma Corp. (NASDAQ:CRME)’s share price was down 2.1% during trading on Monday . The company traded as low as $2.82 and last traded at $2.86, with a volume of 143,900 shares trading hands. The stock had previously closed at $2.92.

A number of equities analysts have commented on CRME shares. Brean Capital restated a “buy” rating and issued a $7.00 price target (down from $10.00) on shares of Cardiome Pharma Corp. in a research report on Monday, August 15th. Zacks Investment Research upgraded shares of Cardiome Pharma Corp. from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Monday, May 16th. Finally, HC Wainwright assumed coverage on shares of Cardiome Pharma Corp. in a research report on Wednesday, June 1st. They set a “buy” rating and a $9.50 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Cardiome Pharma Corp. currently has a consensus rating of “Hold” and an average target price of $8.27.

The firm’s market cap is $91.16 million. The firm’s 50-day moving average is $3.55 and its 200 day moving average is $4.49.

Cardiome Pharma Corp. (NASDAQ:CRME) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.18. The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $6.73 million. During the same quarter last year, the company posted ($0.43) earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities research analysts predict that Cardiome Pharma Corp. will post ($0.75) EPS for the current fiscal year.

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.